Waldemar Placek

Waldemar Placek

Auto-generated profile, based on publicly available information

Waldemar Placek

Department and Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Al. Wojska Polskiego 30, 10-959 Olsztyn, Poland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Jan Maciej KapałaJan Maciej Kapała
Jan Maciej Kapała
JLJulia Alicja Lewandowska
Julia Alicja Lewandowska
WPWaldemar Placek
Waldemar Placek
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
Isotretinoin (ISO) is an oral prescription-only retinoid, well known for its acne-treating effect. However, it affects a substantial number of human cell types, causing a broad spectrum of adverse effects. The purpose of this study is to establish the isotretinoin therapy adverse events among human clinical trials and their prevalence. Two authors (J.K., J.L.) systematically performed the literature review and assessment from December 2021–February 2022. Three databases (PubMed, ClinicalTrials, and Cochrane Library) were searched using the following terms: “isotretinoin acne vulgaris” for published studies in English from 1980–2021. Finally, 25 randomized controlled clinical trials (RCTs) and five open-label clinical trials provided 3274 acne vulgaris suffering patients. Isotretinoin therapy affects almost all of the systems in the human body, causing numerous adverse events. However, they mainly concern mild mucocutaneous conditions (severe cases are rare) and represent individual responses to a drug. In addition, all adverse events are reversible and can be avoided by specific preparations.

Verified
Journal Article
Open access
PDF file
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
Magdalena Krajewska-WłodarczykMagdalena Krajewska-Włodarczyk
Magdalena Krajewska-Włodarczyk
MKMarta Kasprowicz-Furmańczyk
Marta Kasprowicz-Furmańczyk
WPWaldemar Placek
Waldemar Placek
The natural course of psoriasis is the appearance of new lesions in the place of previous ones, which disappeared after a successful therapy. Recent studies of psoriasis etiopathogenesis showed that after psoriatic plaques have disappeared, in healthy skin we can still find a trace of inflammation in the form of tissue resident memory cells (TRM). They are originally responsible for protection against viral and bacterial infections in non-lymphatic tissues. In psoriatic inflammation, they are characterized by heterogeneity depending on their origin. CD8+ T cells TRM are abundantly present in psoriatic epidermis, while CD4+ TRM preferentially populate the dermis. In psoriasis, epidermal CD8+ TRM cells express CLA, CCR6, CD103 and IL-23R antigen and produce IL-17A during ex vivo stimulation. However, CD4+ CD103+ TRM can also colonize the epidermis and produce IL-22 during stimulation. Besides T cells, Th22 and epidermal DCs proved that epidermal cells in healed skin were still present and functioning after several years of disease remission. It explains the clinical phenomenon of the tendency of psoriatic lesions to relapse in the same location and it allows to develop new therapeutic strategies in the future.

26 July 2021 in Medicina
Verified
Journal Article
Open access
PDF file
Natalia ZdanowskaNatalia Zdanowska
Natalia Zdanowska
MKMarta Kasprowicz-Furmańczyk
Marta Kasprowicz-Furmańczyk
WPWaldemar Placek
Waldemar Placek
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
By participating in both the recruitment and activation of T lymphocytes, macrophages and neutrophils at the site of psoriatic inflammation, chemokines play an important role in the pathogenesis of psoriasis and, crucially, may be one indicator of the response to the systemic treatment of the disease. As a result of their major involvement in both physiological and pathological processes, both chemokines and their receptors have been identified as possible therapeutic targets. Due to their presence in the inflammatory process, they play a role in the pathogenesis of diseases that often coexist with psoriasis, such as atherosclerosis and psoriatic arthritis. Chemokines, cytokines and adhesion molecules may be biological markers of disease severity in psoriasis. However, the mechanism of inflammation in psoriasis is too complex to select only one marker to monitor the disease process and improvement after treatment. The aim of this review was to summarize previous reports on the role of chemokines in the pathogenesis of psoriasis, its treatment and comorbidities.

MOMałgorzata Orylska-Ratyńska
Małgorzata Orylska-Ratyńska
WPWaldemar Placek
Waldemar Placek
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
Tetracyclines are a group of antibiotics whose first representative was discovered over 70 years ago. Since then, they have been of great interest in dermatology. In addition to their antibacterial activity, they are able to inhibit metalloproteinases and exhibit anti-inflammatory, anti-apoptotic and antioxidant effects. The side effects have been thoroughly studied over the years, the most characteristic and important ones in daily dermatological practice being: phototoxicity, hyperpigmentation, onycholysis, photoonycholysis, induced lupus erythematosus, and idiopathic intracranial hypertension. In this article, we summarize the use of tetracyclines in infectious diseases and inflammatory dermatoses, and further discuss the instances where the efficacy and safety of tetracyclines have been highlighted over the past few years.

3 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
LLLesław Bernard LAHUTA
Lesław Bernard LAHUTA
Magdalena LigorMagdalena Ligor
Magdalena Ligor
WPWaldemar Placek
Waldemar Placek
RGRyszard Józef Górecki
Ryszard Józef Górecki
Bogusław BuszewskiBogusław Buszewski
Bogusław Buszewski
Introduction: Myo-inositol and its derivatives cyclitols play an important role in the processes of cell regulation, signal transduction, osmoregulation, and ion channel physiology, and are a component of the cell membrane. Free cyclitols present in food or released during the degradation of galactosyl cyclitols by bacteria (in digestive tract) show some physiological benefits. Aim: The aim of this paper is to present and analyze the documented data about curative and healing properties of cyclitols. Results and discussion: Cyclitols are well known compounds in the treatment of an accompanied diabetes insulin resistance, and also obesity and polycystic ovarian syndrome. d-chiro-Inositol deficiency exacerbates insulin resistance in the liver, muscles, and fat, while depletion of myo-inositol results in the development of diabetic complications. Cyclitols are successfully applied in treatment of polycystic ovarian syndrome, simultaneous are observed effective reducing of BMI, improving the hormonal profile, and increasing fertility. Moreover, cyclitols have anti-atherogenic, anti-oxidative, anti-inflammatory, and anti-cancer properties. Conclusion: The properties of cyclitols may be a good therapeutic option in the reduction of metabolically induced inflammation. Due to well drugs tolerance and low toxicity of these compounds, cyclitols are recommend for pregnant women and also for children. Another advantage is their widespread presence and easy availability, which encourages their use in medicine.

29 October 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
HAHubert Aleksandrowicz
Hubert Aleksandrowicz
Agnieszka Owczarczyk-SaczonekAgnieszka Owczarczyk-Saczonek
Agnieszka Owczarczyk-Saczonek
WPWaldemar Placek
Waldemar Placek
The prevalence of venous leg ulcers (VLUs) differs between 1.5% and 3% in the general population. The challenge in treating VLUs is common recurrence. Moreover, VLUs can be resistant to healing, despite appropriate treatment. In these cases, advanced wound therapies should be considered. The number of new technologies, applied in VLUs treatment, has increased in the last years. These therapies include biophysical interventions such as ultrasound therapy, electrical stimulations, electromagnetic therapy, or phototherapy. Furthermore, stem cell therapies, biologic skin equivalents, platelet-rich plasma therapy, oxygen therapies, anti-TNF therapy, or negative pressure wound therapy are advanced venous ulcer therapeutic methods that may support the standard of care. Medical devices, such as a muscle pump activator, or intermittent pneumatic compression device, may be especially useful for specific subgroups of patients suffering from VLUs. Some of the above-mentioned technologies require broader evidence of clinical efficacy and are still considered experimental therapies in dermatology.